Hearing Loss, Sensorineural, Hearing Loss, Sudden, Intratympanic Injection
Conditions
Keywords
drug delivery, Dexamethasone, Hyaluronic acid
Brief summary
This study is a prospective, randomized pilot study. To verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.
Detailed description
The goal of this clinical trial (pilot study) is to evaluate the Efficacy and Safety of Combined Hyaluronic Acid and Dexamethasone Treatment in Patients with Hearing Loss. The main questions it aims to answer are: • Q1. Verification of safety, • Q2. Therapeutic effect of drug injection on sensorineural hearing loss. Participants will undergo several assessment tests (Verification of adverse effects in the external and middle ear through endoscopy, Confirmation of adverse effects through imaging, Hearing test to check for additional hearing loss, Check if subjective ear fullness persists for more than a week aside from the drug effect). If there is a comparison group: Researchers will compare dexamethasone and hyaluronic acid to verify hearing improvement and safety.
Interventions
DRUGDexamethasone
Dexamethasone 5mg/ml
DRUGHyaluronic acid
Hyaluronic Acid 20mg/2ml
ICG 25mg
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with sudden hearing loss, Meniere's disease, ototoxic hearing loss, and noise-induced hearing loss of 25dB HL at the frequency at which hearing loss occurs as a result of pure tone hearing test * Patients whose original hearing ability has not been restored with existing standard treatment (oral, intravenous steroids) * Those who have not participated in clinical trials within 3 months are selected as subjects
Exclusion criteria
* Pregnant or lactating women * When accompanied by lesion, infection, or anatomical deformity of the outer ear, middle ear, or inner ear * Those with liver disease or metabolic disease or a history thereof * History of hypersensitivity to indocyanine green or iodine hypersensitivity * History of ear surgery * Cases with posterior labyrinth lesions * Patients with a history of hypersensitivity to the ingredients of this drug * In addition, serious diseases such as end-stage renal disease, end-stage liver disease, cardiovascular surgery, progressive brain tumor, progressive hemorrhage, and progressive cerebral hemorrhage are included Cases with brain disease and cancer are excluded from the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Analysis of Side Effect Rate through tympanic membrane endoscopy Imaging in 26 participants | 0, 1day and 1 week after intratympanic injection | Confirming healing time of perforation and inflammation (Safety) |
| Analysis of Drug Duration through CT Imaging in 26 participants | 0, 1day and 1 week after intratympanic injection | Checking a time duration of drug in middle and inner ear (Durability) |
| Comparison of Auditory Threshold Values Between Two Groups to Confirm Treatment Efficacy in 26 participants | 0, 1day, 1 week and/or 1 month after intratympanic injection | Verifying therapeutic effect of intratympanic drug delivery vehicle (Efficacy) |
Outcome results
None listed